|
1
|
National Cancer Institute, . Cancer Stat
Facts: Cancer of Any Site. Available from:
https://seer.cancer.gov/statfacts/html/all.html. December
16–2019
|
|
2
|
Wildiers H, Heeren P, Puts M, Topinkova E,
Janssen-Heijnen ML, Extermann M, Falandry C, Artz A, Brain E,
Colloca G, et al: International Society of Geriatric Oncology
consensus on geriatric assessment in older patients with cancer. J
Clin Oncol. 32:2595–2603. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hurria A, Togawa K, Mohile SG, Owusu C,
Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, et
al: Predicting chemotherapy toxicity in older adults with cancer: A
prospective multicenter study. J Clin Oncol. 29:3457–3465. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Borghaei H, Paz-Ares L, Horn L, Spigel DR,
Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al:
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell
lung cancer. N Engl J Med. 373:1627–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al CheckMate 025 Investigators, : Nivolumab versus
everolimus in advanced renal-cell carcinoma. N Engl J Med.
373:1803–1813. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kang Y-K, Boku N, Satoh T, Ryu M-H, Chao
Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in
patients with advanced gastric or gastro-oesophageal junction
cancer refractory to, or intolerant of, at least two previous
chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised,
double-blind, placebo-controlled, phase 3 trial. Lancet.
390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garon EB, Rizvi NA, Hui R, Leighl N,
Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L,
et al KEYNOTE-001 Investigators, : Pembrolizumab for the treatment
of non-small-cell lung cancer. N Engl J Med. 372:2018–2028. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Elias R, Morales J, Rehman Y and Khurshid
H: Immune checkpoint inhibitors in older adults. Curr Oncol Rep.
18:472016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Elias R, Karantanos T, Sira E and
Hartshorn KL: Immunotherapy comes of age: Immune aging &
checkpoint inhibitors. J Geriatr Oncol. 8:229–235. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tomihara K, Curiel TJ and Zhang B:
Optimization of immunotherapy in elderly cancer patients. Crit Rev
Oncog. 18:573–583. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Czesnikiewicz-Guzik M, Lee WW, Cui D,
Hiruma Y, Lamar DL, Yang ZZ, Ouslander JG, Weyand CM and Goronzy
JJ: T cell subset-specific susceptibility to aging. Clin Immunol.
127:107–118. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Weng NP, Akbar AN and Goronzy J: CD28(−) T
cells: Their role in the age-associated decline of immune function.
Trends Immunol. 30:306–312. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Filaci G, Fravega M, Negrini S, Procopio
F, Fenoglio D, Rizzi M, Brenci S, Contini P, Olive D, Ghio M, et
al: Nonantigen specific CD8+ T suppressor lymphocytes
originate from CD8+CD28− T cells and inhibit
both T-cell proliferation and CTL function. Hum Immunol.
65:142–156. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Loh KP, Wong ML and Maggiore R: From
clinical trials to real-world practice: Immune checkpoint
inhibitors in older adults. J Geriatr Oncol. 10:384–388. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: Development and validation. J Chronic Dis.
40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nishijima TF, Deal AM, Williams GR,
Guerard EJ, Nyrop KA and Muss HB: Frailty and inflammatory markers
in older adults with cancer. Aging (Albany NY). 9:650–664. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sato Y, Gonda K, Harada M, Tanisaka Y,
Arai S, Mashimo Y, Iwano H, Sato H, Ryozawa S, Takahashi T, et al:
Increased neutrophil-to-lymphocyte ratio is a novel marker for
nutrition, inflammation and chemotherapy outcome in patients with
locally advanced and metastatic esophageal squamous cell carcinoma.
Biomed Rep. 7:79–84. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mirili C, Yılmaz A, Demirkan S, Bilici M
and Basol Tekin S: Clinical significance of prognostic nutritional
index (PNI) in malignant melanoma. Int J Clin Oncol. 24:1301–1310.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhang W, Ye B, Liang W and Ren Y:
Preoperative prognostic nutritional index is a powerful predictor
of prognosis in patients with stage III ovarian cancer. Sci Rep.
7:95482017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li D, Yuan X, Liu J, Li C and Li W:
Prognostic value of prognostic nutritional index in lung cancer: A
meta-analysis. J Thorac Dis. 10:5298–5307. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Onodera T, Goseki N and Kosaki G:
Prognostic nutritional index in gastrointestinal surgery of
malnourished cancer patients. Nihon Geka Gakkai Zasshi.
85:1001–1005. 1984.(In Japanese). PubMed/NCBI
|
|
26
|
Singh H, Kim G, Maher VE, Beaver JA,
Pai-Scherf LH and Balasubramaniam S: FDA subset analysis of the
safety of nivolumab in elderly patients with advanced cancers. J
Clin Oncol. 34 (Suppl 15):100102016. View Article : Google Scholar
|
|
27
|
Nosaki K, Saka H, Hosomi Y, Baas P, de
Castro G Jr, Reck M, Wu YL, Brahmer JR, Felip E, Sawada T, et al:
Safety and efficacy of pembrolizumab monotherapy in elderly
patients with PD-L1-positive advanced non-small-cell lung cancer:
Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042
studies. Lung Cancer. 135:188–195. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Spigel D, Schwartzberg L, Waterhouse D,
Chandler J, Hussein M, Jotte R, Stepanski E, Mccleod M, Page R, Sen
R, et al: Is nivolumab safe and effective in elderly and PS2
patients with non-small cell lung cancer (NSCLC)? Results of
CheckMate 153. J Thorac Oncol. 12:S1287–S1288. 2017. View Article : Google Scholar
|
|
29
|
Sattar J, Kartolo A, Hopman WM, Lakoff JM
and Baetz T: The efficacy and toxicity of immune checkpoint
inhibitors in a real-world older patient population. J Geriatr
Oncol. 10:411–414. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Leroy V, Gerard E, Dutriaux C, Prey S, Gey
A, Mertens C, Beylot-Barry M and Pham-Ledard A: Adverse events need
for hospitalization and systemic immunosuppression in very elderly
patients (over 80 years) treated with ipilimumab for metastatic
melanoma. Cancer Immunol Immunother. 68:545–551. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Muchnik E, Loh KP, Strawderman M, Magnuson
A, Mohile SG, Estrah V and Maggiore RJ: Immune checkpoint
inhibitors in real-world treatment of older adults with non-small
cell lung cancer. J Am Geriatr Soc. 67:905–912. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Handforth C, Clegg A, Young C, Simpkins S,
Seymour MT, Selby PJ and Young J: The prevalence and outcomes of
frailty in older cancer patients: A systematic review. Ann Oncol.
26:1091–1101. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Welaya K, Loh KP, Messing S, Szuba E,
Magnuson A, Mohile SG and Maggiore RJ: Geriatric assessment and
treatment outcomes in older adults with cancer receiving immune
checkpoint inhibitors. J Geriatr Oncol. 11:523–528. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Archibald WJ, Victor AI, Strawderman MS
and Maggiore RJ: Immune checkpoint inhibitors in older adults with
melanoma or cutaneous malignancies: The Wilmot Cancer Institute
experience. J Geriatr Oncol. 11:496–502. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gleason LJ, Benton EA, Alvarez-Nebreda ML,
Weaver MJ, Harris MB and Javedan H: FRAIL questionnaire screening
tool and short-term outcomes in geriatric fracture patients. J Am
Med Dir Assoc. 18:1082–1086. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Facon T, Dimopoulos MA, Meuleman N, Belch
A, Mohty M, Chen WM, Kim K, Zamagni E, Rodriguez-Otero P, Renwick
W, et al: A simplified frailty scale predicts outcomes in
transplant-ineligible patients with newly diagnosed multiple
myeloma treated in the FIRST (MM-020) trial. Leukemia. 34:224–233.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Santini FC, Rizvi H, Plodkowski AJ, Ni A,
Lacouture ME, Gambarin-Gelwan M, Wilkins O, Panora E, Halpenny DF,
Long NM, et al: Safety and efficacy of re-treating with
immunotherapy after immune-related adverse events in patients with
NSCLC. Cancer Immunol Res. 6:1093–1099. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Simonaggio A, Michot JM, Voisin AL, Le
Pavec J, Collins M, Lallart A, Cengizalp G, Vozy A, Laparra A,
Varga A, et al: Evaluation of readministration of immune checkpoint
inhibitors after immune-related adverse events in patients with
cancer. JAMA Oncol. 5:13102019. View Article : Google Scholar
|
|
39
|
Dolladille C, Ederhy S, Sassier M, Cautela
J, Thuny F, Cohen AA, Fedrizzi S, Chrétien B, Da-Silva A, Plane AF,
et al: Immune checkpoint inhibitor rechallenge after immune-related
adverse events in patients with cancer. JAMA Oncol. 6:8652020.
View Article : Google Scholar
|
|
40
|
Bowen RC, Little NAB, Harmer JR, Ma J,
Mirabelli LG, Roller KD, Breivik AM, Signor E, Miller AB and Khong
HT: Neutrophil-to-lymphocyte ratio as prognostic indicator in
gastrointestinal cancers: A systematic review and meta-analysis.
Oncotarget. 8:32171–32189. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106:dju1242014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kato K, Masuishi T, Fushiki K, Nakano S,
Kawakami T, Kawamoto Y, Narita Y, Tsushima T, Nakatsumi H, Kadowaki
S, et al: Impact of tumor growth rate during preceding treatment on
tumor response to nivolumab or irinotecan in advanced gastric
cancer. J Clin Oncol. 37 (Suppl 4):842019. View Article : Google Scholar : PubMed/NCBI
|
